- Home
- ALLR vs EDSA Comparison
ALLR vs EDSA Comparison
Compare ALLR & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- EDSA
- Stock Information
- Founded
- ALLR 2004
- EDSA 2015
- Country
- ALLR United States
- EDSA Canada
- Employees
- ALLR N/A
- EDSA N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- ALLR Health Care
- EDSA Health Care
- Exchange
- ALLR Nasdaq
- EDSA Nasdaq
- Market Cap
- ALLR 15.8M
- EDSA 13.8M
- IPO Year
- ALLR N/A
- EDSA N/A
- Fundamental
- Price
- ALLR $1.01
- EDSA $2.09
- Analyst Decision
- ALLR
- EDSA Strong Buy
- Analyst Count
- ALLR 0
- EDSA 2
- Target Price
- ALLR N/A
- EDSA $13.00
- AVG Volume (30 Days)
- ALLR 417.1K
- EDSA 13.3K
- Earning Date
- ALLR 08-04-2025
- EDSA 08-08-2025
- Dividend Yield
- ALLR N/A
- EDSA N/A
- EPS Growth
- ALLR N/A
- EDSA N/A
- EPS
- ALLR N/A
- EDSA N/A
- Revenue
- ALLR N/A
- EDSA N/A
- Revenue This Year
- ALLR N/A
- EDSA N/A
- Revenue Next Year
- ALLR N/A
- EDSA N/A
- P/E Ratio
- ALLR N/A
- EDSA N/A
- Revenue Growth
- ALLR N/A
- EDSA N/A
- 52 Week Low
- ALLR $0.61
- EDSA $1.55
- 52 Week High
- ALLR $7.45
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- ALLR 53.22
- EDSA 55.09
- Support Level
- ALLR $0.95
- EDSA $2.03
- Resistance Level
- ALLR $1.08
- EDSA $2.11
- Average True Range (ATR)
- ALLR 0.07
- EDSA 0.10
- MACD
- ALLR 0.01
- EDSA 0.01
- Stochastic Oscillator
- ALLR 59.39
- EDSA 73.33
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.